Publication date: Available online 6 November 2026 Source: Clinical Microbiology and Infection Author(s): Emily G. McDonald, Nicole Ezer, Mathew P. Cheng, Zahra N. Sohani, Todd C. Lee
Is a lower dose of trimethoprim sulfamethoxazole for Pneumocystis jirovecii pneumonia just as effective, but safer?. // Clinical Microbiology and Infection. – URL: https://www.sciencedirect.com/science/article/pii/S1198743X26006178?dgcid=rss_sd_all
Is a lower dose of trimethoprim sulfamethoxazole for Pneumocystis jirovecii pneumonia just as effective, but safer?. Clinical Microbiology and Infection. https://www.sciencedirect.com/science/article/pii/S1198743X26006178?dgcid=rss_sd_all
“Is a lower dose of trimethoprim sulfamethoxazole for Pneumocystis jirovecii pneumonia just as effective, but safer?.” Clinical Microbiology and Infection.
@article{article41003,
title = {Is a lower dose of trimethoprim sulfamethoxazole for Pneumocystis jirovecii pneumonia just as effective, but safer?},
journal = {Clinical Microbiology and Infection},
url = {https://www.sciencedirect.com/science/article/pii/S1198743X26006178?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...